ArticleMolecular and cellular biochemistry2026
FABP3 deficiency exacerbates renal Randall plaque formation: insights from single-cell RNA transcriptomic analysis.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Randall’s plaque (RP) formation is a critical initiating process in calcium oxalate nephrolithiasis; however, the molecular mechanisms driving its pathogenesis remain incompletely understood. This study aimed to evaluate the role of fatty acid-binding protein 3 (FABP3), a key regulator of lipid metabolism and epithelial homeostasis, in RP development. We employed an integrative multi-omics approach incorporating single-cell RNA sequencing (scRNA-seq), quantitative real-time PCR (qPCR), immunohistochemistry (IHC), and pathway enrichment analyses on human renal papillary tissues from individuals with and without RP, alongside validation in a murine model. scRNA-seq revealed significant downregulation of FABP3 across 21 renal cell clusters within the RP microenvironment (mean expression: 0.0188). qPCR confirmed a tenfold reduction in FABP3 transcript levels in RP samples compared to controls (2^-ΔCt: 0.0714 vs. 0.6998; Cp values 24.05–25.31 vs. 20.97–22.77; p < 0.001), while IHC demonstrated parallel protein depletion in murine RP tissues. Functional enrichment analyses linked FABP3 deficiency to dysregulation of lipid metabolic pathways, including fatty acid transport and lipolysis, implicating these alterations in interstitial calcium deposition and plaque formation. In conclusion, this study identifies FABP3 as a central molecular determinant in RP pathogenesis, offering novel mechanistic insight and establishing FABP3 as a promising biomarker and therapeutic target for nephrolithiasis prevention.
Indexed as
Identifiers
41324865What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.